U.S. Markets closed

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.58-0.24 (-2.72%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.82
Open8.79
Bid8.52 x 900
Ask8.89 x 800
Day's Range8.53 - 8.90
52 Week Range3.60 - 11.74
Volume280,287
Avg. Volume277,062
Market Cap370.447M
Beta (5Y Monthly)0.35
PE Ratio (TTM)N/A
EPS (TTM)-0.31
Earnings DateNov 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.88
  • CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue
    PR Newswire

    CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K.

  • CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
    PR Newswire

    CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the immediate appointment of James Komsa as Vice President - U.S. Sales and Marketing.

  • Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
    PR Newswire

    Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces that Health Canada has granted Medical Device Authorization for the importation, sale, and emergency use of CytoSorb in hospitalized COVID-19 patients under Interim Order (IO) ID 316575. CytoSorbents will collaborate with ebbtides medical, a specialty distributor of medical products throughout Canada, to ensure rapid and widespread availability of the therapy.